European Union - English - EMA (European Medicines Agency)

intervet international bv - ibafloxacin - antibacterials for systemic use - dogs; cats - dogs:ibaflin is indicated for the treatment of the following conditions in dogs:dermal infections (pyoderma - superficial and deep, wounds, abscesses) caused by susceptible strains of staphylococci, escherichia coli and proteus mirabilis;acute, uncomplicated urinary-tract infections, caused by susceptible strains of staphylococci, proteus species, enterobacter spp., e. coli and klebsiella spp.;respiratory-tract infections (upper tract) caused by susceptible strains of staphylococci, e. coli, and klebsiella spp.ibaflin gel is indicated in dogs for the treatment of the following conditions:dermal infections (pyoderma - superficial and deep, wounds, abscesses) caused by susceptible pathogens such as staphylococcus spp., e. coli and p. mirabilis.cats:ibaflin gel is indicated in cats for treatment of the following conditions:dermal infections (soft-tissue infections - wounds, abscesses) caused by susceptible pathogens such as staphylococcus spp., e. coli, proteus spp. and pasteurella spp.;upper respiratory-tract infections caused by susceptible pathogens such as staphylococcus spp., e. coli, klebsiella spp. and pasteurella spp.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ibafloxacin - oral tablet - ibafloxacin antibiotic active 300.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - infections of the respiratory tract | infections of the urinary tracts | organisms sensitive to ibafloxacin | pyoderma | soft tissue infections | abscesses | acute respiratory infections | anal sacculitis | bronchiseptica | bronchitis | escherichia coli | gingivitis | group d streptococcus | klebsiella spp. | pharyngitis | pneumonia | post-parturient infections | proteus spp. | pseudomonas aeruginosa | pyoderma | septicaemia | staphylococcus spp. | tonsillitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ibafloxacin - oral gel - ibafloxacin antibiotic active 30.0 mg/ml - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - infections of the respiratory tract | infections of the skin | infections of the urinary tracts | pyoderma | soft tissue infections | abscesses | acute respiratory infections | anal sacculitis | bronchiseptica | bronchitis | escherichia coli | fungal | gingivitis | gram negative bacteria | gram positive bacteria | group d streptococcus | klebsiella spp. | pharyngitis | pneumonia | post-parturient infections | proteus spp. | pseudomonas aeruginosa | pyoderma | septicaemia | staphylococcus spp. | tonsillitis | yeast

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ibafloxacin - unknown - ibafloxacin antibiotic active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4) ].  moxifloxacin tablets are indicated in adult patients f

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4) ].  moxifloxacin tablets are indicated in adult patients f

United States - English - NLM (National Library of Medicine)

torrent pharmaceuticals limited - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), homophiles influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies ( 14.3)]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or stre

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]) , haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3)] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]) , haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3)] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4)]. moxifloxacin t

United States - English - NLM (National Library of Medicine)

alvogen, inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - moxifloxacin hydrochloride is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]),  haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3 )] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin hydrochloride is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4 )]. moxifloxacin hydrochloride is indicated in